Immune Reaction And Protective Efficacy Of Inoculaing Mixed Antigens Of Helicobacter Pylori Throught Three Different Mucosal Routes

It is estimated that Helicobacter pylori (H. pylori), a Gram-negative, spiral, microaerophilic bacterium, infects the stomachs of over 50% of the world's population and if not treated it can cause, in certain individuals, chronic gastritis, peptic ulcer disease, gastric adenocarcinoma and gastric mucosa-associated lymphoid tissue (MALT) lymphoma. WHO had classified H.pylori as grade I carcinogen in 1994. Current therapies based on a proton-pump inhibitor and antibiotics have several drawbacks, including patient compliance, antibiotic resistance and recurrence of infection. Therefore, there would be tremendous benefit to the society if safe, effective, and cost-effective vaccines were available to prevent or cure chronic H. pylori infection. Efforts for vaccine development against infection with H.pylori have focused on antigens that are involved in the pathogenesis of the bacterium and routes...